Flashcards in reproductive Deck (65):
1
leuprolide MOA
gnRh agnoist
2
ethiny estradiol MOA
Er agonist
3
DES MOA
ER agnoist
4
mestranol MOA
ER agonist
5
clomiphene MOA
anatg of ER at the hypothalamus
6
tamoxifen MOA
antag at breast
ag at bone
ag at endometrium
7
raloxifene MOA
antag at breast
ag at bone
antag at endometrium
8
anastrozole MOA
aromatase inhibitor
9
exemestane MOA
aromatase inhibitor
10
progestin MOA
progestoerone receptor agonist
11
mifepristone Ru-486 MOA
competitive inhibitor of progestins at the PR
12
terbutaline MOA
b2 agonist
13
ritodrine MOA
b2 agonist
14
danazol MOA
synthetic androgen that acts as partial agonist at androgen receptors
15
testosterone MOA
agonist at AR
16
methyltestosterone MOA
agonist at AR
17
finasteride MOA
inhibits 5 alpha reductase
18
flutamide MOA
nonsteroidal competitive inhibitor at AR
19
ketoconazole MOA
inhibites seroid syntheisis @ 17, 20 desmolase
20
spironolactone MOA
inhibites steroid binding, 17 alpha hydroxylase, 17,20 desmolase
21
tamsulosin MOA
alpha 1 antqagonist
22
sidenafil/vardenafil/tadalafil MOA
inhibit PDE5
23
minoxidil MOA
direct arteriolar vasodilator
24
uses of leuprolide
moa = GnRH agonist
pulsatile: infertility
contiuous: prostate cancer after flutamide blocks ar
continous: uterine fibroids
continuous: precocious puberty
25
usese of ethinyl estradiol, DES and mestranol
ER agonists
hypogonadism or ovarina gailure
menstural abrnoamlities, HRT in post menopa
men with androgen dependent prostate cancer
26
use of clomiphene
inhibits ER at the hypothalamus
PCOS infertility treatmetn vrs anovulation
27
use of tamoxifen
antag at breast
ag at bone
ag at endo
to treat and prevent ER/PR positive breast cancer
28
use of raloxifen
antag at breast
ag at bone
antag at end
osteoporosis
29
use of HRT
prevent and reliefe menopausal symptoms
osteoporosis
30
use of anastrozole
aromatse inhibitors
postmenopausal women wit ER positive breast cancer
31
used of exemestane
aromatase inhibitors
postemenopausal women with ER posirive breast cnacners
32
use of progestins
PR ags
UCp
endometrial cancer
abnormal uterine bleeding
33
use of mifepristone
competitive inhibitor of PR
termination of pregos with misoprostal
34
use of terbutaline
b2 agonist
decreases freqency of contractions of women in labour
35
use of ritodrine
b2 agonist
decreases frequency of contractions of women in labour
36
use of danazol
synthetic androgen with partial agonist at androgen receptors
endometriosis
herediratary angioedema
37
uest of testosterone and metyhltestosterone
ag at AR
hypogonadism
promotes development of secondary sex characteristics
stimulatio of anablosim to recovery after burn and injuery
38
use of finasteride
5a reductased inhibitor
BPH
male patterened baldness
39
use of flutamide
nonsteroidal competitive inhibitor of AR
prostate carcinoma wtih leuprolide
40
use of ketoconazole
inhibites steroid synthesis/inhibits 17,20 desmolase
treat PCOS to reduce androgenic symptoms
41
use of spironolactone
inhibites steroid binding, 17 OHase, 17,2 desmolase
treats PCOS to reduces andogenic symptoms
42
use of tamsulosin
alpha1a/d antagonist
treast BPH
43
use of sildenafil/v ardenafil/tadalafil
inhibits PDE5
erectile dysfunction
44
use of minoxidil
direct arteriolar vasodiation
androgentic alopecia
severe refractory hyertension
45
toxo of minoxidil
direct arterial vasodilater
androgenic alopecia
severe refractory hypertension
46
toxo of sildenafil/vardenafil/tadalafil
inhibties pDe5
use at erectile dysfucntion
TOXO - headache, flushing, dysepsia, cyanopsia, hypotension with nitrates
47
toxo of tamsulosin
alpha1a/d antag
used at BPH
no toxo listed
48
toxo of spironolactone
inhibit steroid binding, 17 alpha OHase, 17, 20 desmolase
PCOS androgenic a/se
gynecomastia and amenorrhoea
49
toxo of ketoconazole
inhibits steroid synthesis, 17,20 desmolase
PCOS androgenic a/se
gynecomastia and amenorrhea
50
toxo of testosterone adn methyltestosteron
ag at AT
hypogonasdism, promotes development of secondary sexual characteristics, promotes healing @ anabolism in burns and injury
51
toxo of danazole
synthetic androgen, partial agnoist at androgen receptorp
@ endometriosis and hereditary angioedema
TOXO - weight gain, edema, acne, hirsutisim, masculinizaiton, decreased HDL levels and HEPATOTOXICITY
52
hepatotosicity
danazole
53
toxo fo terbutaline and riodrine
beta 2 agonists uterine relax
decreased freqeuncy of uterine contractions in labour
none listed
54
toxo of oral conctraceptvives
increased risk of vs in smokers over 35
55
toxo of mifepristone RU-486
progestin receptor competitive inhibitor
termination of pregos with misoprostol/PGE1
heavy bleeding, gi effects (n/a/anorexia), abdominal pain
56
toxo of progestin
progestin receptor agonist, decrease grwtoh and icnreases vascularization of endom
@ oral contraceptins, endometrial cancer and abnormal uterine bleeding
57
toxo of anastrozole
aromatase inhibit
used for postmenopausla women with ER positive breast cancer
no toxo listed
58
toxo of exemestane
aromatase inhibit
used in postmenopausal women with ER positive breast coancer
no toxo listed
59
toxo of raloxifene
antag breast
antag endo
ag bone
for osteoporosis
increased risk of thromboembooic events
60
toxo of tamoxifene
antag at breast
ag at bone
ag at endo
used at ER/PR breast cancer tx and prevent
toxo - icnreasd thromboemoblic events, icnreased endometrial cancer
61
toxo fo clomiphene
antag of ER at hypothalamus
infertility at PCOs by ovuation induction
hot flashes
ovarina enlargementh
multiple simultaneous pregos
visual disturbances
62
two drugs that can cause visual changes
clomiphene - hypothalalmus ER antag
sidenafil - cyanopsia inhibit PDE5
63
toxo of mestranol
ER agonist
hypogonadism or ovarina failure, menstrual abonromalties, HRT, men with androgen dependent prostate cancers
TOXO: increase risk of endometrial cancer, bleeding post menopausal woen, clear cella denomarcinom in vaigna, increase rick of thrmobi
64
where are mestranol, DES, ethinylestradiol contraindicated
Er positive breast cancer (treat with anastrozole and exemestane aromatse inhibitors)
historoy of DVT
65